VV Venture Valuation

VV Venture Valuation focus is on technology companies in fast growing markets and industries including pharmaceuticals, Biotechnology.

Venture Valuation was founded in 1999 based on research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and patents. Our focus is on technology companies in fast growing markets and industries including pharmaceuticals, Biotechnology, Medical Technology (Med Tech), nanotechnology, renewable energies (cleantech) and information technology (IT) / computer science / software. Our clients include companies domiciled on almost all continents. We perform reviews both for investors as well as for companies themselves. In addition to our assessment services in Life Sciences, in 2003 we established the 'Swiss Life Sciences Database '; the cornerstone of our global company and Licensing Deal database 'Biotechgate' (www.biotechgate.com). Biotechgate is now an independent business unit within Venture Valuation. The portal has become a premier information hub (Information Broker) for all potential stakeholders in the biotechnology, pharmaceutical and medical technology fields: A wealth of data on life science related companies, products, licensing opportunities, licensing deals, financing (financing rounds) and much more can be viewed, analysed, processed and downloaded. At Venture Valuation, we always place experienced internal consultants and analysts in all the services we offer. In addition to the scientific expertise our experts provide, we also rely on a network of established partners to meet all of your needs. This allows us to build a comprehensive understanding of our clients' businesses - and to support you during your growth phase.